Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: A randomized trial

JAMA

Volumn 293, Issue 6, 2005, Pages 681-689

  Fiessinger, Jean Noel ^b   Huisman, Menno V ^a   Davidson, Bruce L ^c   Bounameaux, Henri ^d   Francis, Charles W ^e   Eriksson, Henry ^f   Lundström, Torbjörn ^g   Berkowitz, Scott D ^h   Nyström, Per ^g   Thorsén, Mona ^g   Ginsberg, Jeffrey S ⁱ  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g ASTRAZENECA R AND D   (Sweden)

^h ASTRAZENECA   (United Kingdom)

ⁱ MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; BILIARY TRACT DISEASE; BLEEDING; CHOLECYSTITIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HEPATORENAL SYNDROME; HUMAN; LIVER TOXICITY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZATION; RECURRENT DISEASE; RISK; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 13444278653     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.6.681     Document Type: Article

References (24)

1. Hirsh J, Dalen JE, Andersen DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001; 119(suppl):8S-21S.
2. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest. 2001;119(suppl):22S-38S.
3. Eriksson UG, Bredberg U, Gislén K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol. 2003;59:35-43.
4. Gustafsson D, Nyström J-E, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res. 2001;101:171-181.
5. Klement P, Carlsson S, Rak J, et al. The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. J Thromb Haemost. 2003;1:587-594.
6. Eriksson UG, Bredberg U, Hoffman K-J, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2003;31:294-305.
7. Bredberg E, Andersson TB, Frison L, et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet. 2003;42:765-777.
8. Francis CW, Berkowitz SD, Comp PC, et al. for the EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003;349:1703-1712.
9. Eriksson BI, Agnelli C, Cohen AT, et al; METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288-296.
10. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691-1698.
11. Schulman S, Wåhlander K, Lundström T, et al; THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349: 1713-1721.
12. Eriksson H, Wåhlander K, Gustafsson D, et al; THRIVE Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost. 2003;1: 41-47.
13. Siegel JP. Equivalence and noninferiority trials. Am Heart J. 2000;139:S166-S170.
14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Guidelines. Available at: http://www.ich.org. Accessibility verified January 12, 2005.
15. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326: 975-982.
16. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
17. Charbonnier BA, Fiessinger JN, Banga JD, Wenzel E, d'Azemar P, Sagnard L; FRAXODI group. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. Thromb Haemost. 1998;79:897-901.
18. Koopman MM, Prandoni P, Piovella F, et al; Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682-687.
19. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337:657-662.
20. Buller HR, Davidson BL, Decousus H, et al; the Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004; 140:867-873.
21. Merli G, Spiro TE, Olsson CG, et al; Enoxaparin Clinical Trial Group. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 2001;134:191-202.
22. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.
23. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162:1729-1735.
24. Wallentin L, Wilcox RC, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362:789-797.